Meet Your Healthcare Provider

Dr. Sridhar Chaganti is a consultant haemato-oncologist at the University Hospital Birmingham (UHB), UK, with a clinical focus on lymphomas, acute lymphoblastic leukaemia (ALL), stem cell transplantation, and immune effector cell therapies, including CAR T-cell therapy. He serves as the clinical lead for the CAR T Programme and lymphoid diseases at UHB.

His research interests include aggressive lymphomas and immune-based therapies, particularly CAR T-cell therapy. Dr. Chaganti is Chair of the UK High Grade Lymphoma Research Study Group, Co-Chair of the UK National CAR T Panel, and former Chair of the British Society for Haematology (BSH) Lymphoma Special Interest Group.

He is an author or co-author of numerous scientific publications and BSH guidelines and serves as a clinical expert for NICE technology appraisals and scientific advice committees. In addition, Dr. Chaganti is a chief investigator and principal investigator for several clinical trials.